Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.
Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D, Barbacid M. Ambrogio C, et al. Among authors: nadal e. Nat Med. 2016 Mar;22(3):270-7. doi: 10.1038/nm.4041. Epub 2016 Feb 8. Nat Med. 2016. PMID: 26855149
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R. Mainardi S, et al. Among authors: nadal e. Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28. Nat Med. 2018. PMID: 29808006 Free article.
Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M, Rullan AJ, Saigí M, Peiró I, Montanya E, Palmero R, Ruffinelli JC, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Cardenal F, Nadal E. Bergamino M, et al. Among authors: nadal e. BMC Cancer. 2019 Feb 21;19(1):165. doi: 10.1186/s12885-019-5370-5. BMC Cancer. 2019. PMID: 30791870 Free PMC article.
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.
Fernandes Neto JM, Nadal E, Bosdriesz E, Ooft SN, Farre L, McLean C, Klarenbeek S, Jurgens A, Hagen H, Wang L, Felip E, Martinez-Marti A, Vidal A, Voest E, Wessels LFA, van Tellingen O, Villanueva A, Bernards R. Fernandes Neto JM, et al. Among authors: nadal e. Nat Commun. 2020 Jun 22;11(1):3157. doi: 10.1038/s41467-020-16952-9. Nat Commun. 2020. PMID: 32572029 Free PMC article.
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Nokin MJ, Darbo E, Travert C, Drogat B, Lacouture A, San José S, Cabrera N, Turcq B, Prouzet-Mauleon V, Falcone M, Villanueva A, Wang H, Herfs M, Mosteiro M, Jänne PA, Pujol JL, Maraver A, Barbacid M, Nadal E, Santamaría D, Ambrogio C. Nokin MJ, et al. Among authors: nadal e. JCI Insight. 2020 Aug 6;5(15):e137869. doi: 10.1172/jci.insight.137869. JCI Insight. 2020. PMID: 32759499 Free PMC article.
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
Aliagas E, Alay A, Martínez-Iniesta M, Hernández-Madrigal M, Cordero D, Gausachs M, Pros E, Saigí M, Busacca S, Sharkley AJ, Dawson A, Palmero R, Ruffinelli JC, Padrones S, Aso S, Escobar I, Ramos R, Llatjós R, Vidal A, Dorca E, Varela M, Sánchez-Céspedes M, Fennell D, Muñoz-Pinedo C, Villanueva A, Solé X, Nadal E. Aliagas E, et al. Among authors: nadal e. Br J Cancer. 2021 Nov;125(10):1365-1376. doi: 10.1038/s41416-021-01547-y. Epub 2021 Sep 29. Br J Cancer. 2021. PMID: 34588615 Free PMC article.
270 results